InflaRx N.V.
InflaRx N.V. (IFRX): 2 pipeline candidates · 2 clinical trials. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
D/E 0.33 · 0% dilution
Lead: Phase 3
2 candidates
N/A
N/A
A transparent, data-derived signal for InflaRx N.V.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$238.6M
Cash
$1.3M
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| csu lower dose treatment | Phase 2 |
| vilobelimab | Phase 3 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
32
Total value held
$14.7M
| Holder | Shares | Value |
|---|---|---|
| suvretta capital management, llc | 7,933,910 | $7.1M |
| 683 capital management, llc | 3,315,000 | $3.0M |
| bank of america corp /de/ | 1,975,000 | $1.8M |
| morgan stanley | 1,175,576 | $1.1M |
| marshall wace, llp | 554,364 | $493K |
| raymond james financial inc | 395,803 | $354K |
| two sigma investments, lp | 189,075 | $169K |
| dcf advisers, llc | 158,500 | $142K |
| adar1 capital management, llc | 158,271 | $142K |
| kestra advisory services, llc | 95,000 | $85K |
Showing top 10 of 32 institutional holders of InflaRx N.V.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in InflaRx N.V.'s pipeline?
InflaRx N.V. (IFRX) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is InflaRx N.V.'s lead drug candidate?
InflaRx N.V.'s most advanced tracked candidate is csu lower dose treatment (Phase 2) for Chronic Urticaria, Idiopathic.
What is InflaRx N.V.'s market capitalization?
InflaRx N.V.'s market capitalization is approximately $238.6M.
Who is the CEO of InflaRx N.V.?
Prof. Niels C. Riedemann M.D., Ph.D. is the chief executive officer of InflaRx N.V. (IFRX).
Get the full picture on InflaRx N.V.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.